TIAA CREF INVESTMENT MANAGEMENT LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 212 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.

Quarter-by-quarter ownership
TIAA CREF INVESTMENT MANAGEMENT LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2019$4,482,000
-44.7%
40,070
-50.2%
0.00%
-50.0%
Q4 2018$8,104,000
-60.9%
80,407
-51.0%
0.01%
-14.3%
Q3 2018$20,724,000
+175.2%
164,006
+82.8%
0.01%
+40.0%
Q2 2018$7,530,000
+104.5%
89,741
+49.9%
0.01%
+150.0%
Q1 2018$3,682,000
+1.3%
59,858
-3.8%
0.00%0.0%
Q4 2017$3,634,000
-3.7%
62,211
-4.3%
0.00%
-33.3%
Q3 2017$3,773,000
-52.2%
65,010
-0.3%
0.00%
-50.0%
Q2 2017$7,894,000
+9.8%
65,199
+2.6%
0.01%
+20.0%
Q1 2017$7,190,000
+0.7%
63,575
-3.3%
0.01%0.0%
Q4 2016$7,142,000
+0.2%
65,735
+51.8%
0.01%
+25.0%
Q3 2016$7,128,000
+24.2%
43,309
+7.7%
0.00%0.0%
Q2 2016$5,737,000
+10.8%
40,209
-0.2%
0.00%0.0%
Q1 2016$5,177,000
-36.2%
40,297
-25.9%
0.00%
-33.3%
Q4 2015$8,118,000
-45.4%
54,353
-39.4%
0.01%
-50.0%
Q3 2015$14,876,000
-35.7%
89,688
-6.4%
0.01%
-25.0%
Q2 2015$23,130,000
+34.6%
95,825
+57.2%
0.02%
+33.3%
Q1 2015$17,188,000
+184.0%
60,947
+57.1%
0.01%
+200.0%
Q4 2014$6,053,000
-39.6%
38,803
-8.4%
0.00%
-42.9%
Q3 2014$10,027,000
+25.7%
42,365
+25.7%
0.01%
+16.7%
Q2 2014$7,974,000
-42.1%
33,697
-19.3%
0.01%
-40.0%
Q1 2014$13,770,000
-21.3%
41,753
-83.7%
0.01%
-23.1%
Q4 2013$17,486,000
+37.2%
256,088
+38.7%
0.01%
+30.0%
Q3 2013$12,748,000
+1034.2%
184,670
+636.6%
0.01%
+900.0%
Q2 2013$1,124,00025,0710.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders